CareDx
CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.
Top Stages
10 past transactions
MediGO
Acquisition in 2023
MediGO is a logistics platform focused on the real-time management of time-sensitive medical resources, specifically for organ transportation. The platform utilizes proprietary algorithms and machine learning to provide accurate tracking and estimated times of arrival, enhancing supply chain transparency. By offering features such as real-time monitoring of organ location, temperature, and environmental conditions, MediGO allows medical professionals to make informed logistics decisions. Its centralized communication system enables care teams to unify stakeholders and coordinate resources effectively, ultimately optimizing the transplant supply chain. This approach aims to save time, reduce costs, and improve outcomes in organ transplantation.
MedActionPlan
Acquisition in 2021
MedActionPlan operates as a healthcare technology company specializing in medication management solutions for transplant patients. Its core business involves providing web-based tools designed to enhance patient safety and adherence to prescribed medication regimens post-transplant. The platform offers up-to-date medication schedules, reminders, and progress monitoring dashboards, enabling healthcare professionals to streamline care, reduce costs, and improve patient satisfaction. Additionally, MedActionPlan places emphasis on patient education as part of its service offering.
Transplant Hero
Acquisition in 2021
Transplant Hero is a company that develops mobile applications designed to assist transplant patients in managing their medication regimens. Its flagship smartphone app features an alarm system that notifies users when it is time to take their medications. The app also includes interactive logging capabilities, allowing patients to track their medication events effectively. By providing positive reinforcement for medication adherence, Transplant Hero aims to enhance the timely intake of immunosuppression medications, thereby supporting the health and well-being of transplant patients.
Miromatrix Medical
Series C in 2021
Miromatrix Medical Inc. is a biotechnology company focused on developing fully biological human organs and organ-derived products to address the critical shortage of transplantable organs. Utilizing its patented perfusion decellularization and recellularization technology, the company aims to create implantable organs, including bioengineered livers, kidneys, and hearts, as well as advanced wound care solutions. Miromatrix offers a range of products, such as MIROMESH, a non-crosslinked acellular surgical mesh for soft tissue repair, and various MIRODERM wound matrixes designed for managing different types of wounds, including surgical and diabetic ulcers. Founded in 2009 and headquartered in Eden Prairie, Minnesota, Miromatrix Medical serves customers globally, with a commitment to improving patient outcomes through innovative organ and tissue solutions.
BFS Molecular
Acquisition in 2021
BFS Molecular is a global molecular diagnostics company focused on enhancing post-transplantation patient care. It specializes in developing advanced molecular diagnostics software and offers post-transplant monitoring tests that utilize Next Generation Sequencing technology on Illumina platforms. By providing novel testing approaches and delivering high-quality results, BFS Molecular aids physicians in the early detection of transplant rejection and disease relapse, thereby aiming to improve outcomes for patients undergoing transplantation.
TransChart
Acquisition in 2021
TransChart is a company that specializes in patient management software specifically designed for the transplant continuum, addressing the needs of kidney, heart, lung, liver, pancreas (Islet Cell), and small bowel transplants. The software is highly configurable, featuring core functionalities and additional modules that cater to various requirements, including regulatory compliance and data analytics. This enables hospitals and transplant centers to manage patient data and transplant cases more efficiently and effectively. TransChart's solutions aim to enhance the overall transplant process, ensuring that healthcare providers can deliver optimal care to patients in need of organ transplants.
XynManagement
Acquisition in 2019
XynManagement, Inc. is a healthcare analytics company headquartered in Boerne, Texas, specializing in software solutions for transplant quality tracking and waitlist management. Founded in 2014, the company provides tools that address critical challenges faced by transplant centers, enabling professionals to assess candidate and donor risks effectively. Through its flagship product, XynQAPI, XynManagement offers real-time monitoring of center-level performance and facilitates the analysis of quality and outcomes data. By automating quality assurance and performance improvement processes, the company enhances patient care and supports healthcare institutions in making data-driven decisions. XynManagement operates as a subsidiary of CareDx, Inc. as of August 2019.
OTTR Chronic Care Solutions
Acquisition in 2019
OTTR Chronic Care Solutions is a prominent provider of organ transplant patient tracking software, dedicated to enhancing the quality of patient care through efficient workflow management. The company's innovative solutions reduce operational costs and improve case-load efficiency for healthcare clients, including physicians, nurses, and administrators. By offering real-time access to critical information, OTTR's software expedites external reporting and supports clinical research. The company currently serves over 200 programs across more than 60 transplant centers in the United States and Canada, with additional offerings in the United Kingdom, Saudi Arabia, and Australia. Through its commitment to optimizing patient safety and streamlining processes, OTTR has established itself as a leader in the field of transplant software solutions.
Allenex
Acquisition in 2015
Allenex AB is a life science company based in Stockholm, Sweden, focused on developing, manufacturing, marketing, and selling products for the transplantation of blood stem cells and organs globally. The company specializes in genomic Human Leukocyte Antigens (HLA) typing kits used to match donors and recipients before hematopoietic stem cell and organ transplants. Additionally, Allenex offers XM-ONE, a range of products and services tailored for organ transplantation. Its research initiatives include an AB0 column designed for transplants between individuals with different blood groups and an AB0 diagnostic test that assesses blood group antibodies. Allenex distributes its products primarily through sub-distributors to laboratories engaged in transplantation diagnostics. Originally founded in 1998 as LinkMed AB, the company rebranded to Allenex AB in June 2011.
ImmuMetrix
Acquisition in 2014
ImmuMetrix, Inc. is a biotechnology company based in Palo Alto, California, founded in 2010. The company specializes in transplant diagnostics and the development of immune profiles, which are utilized in the treatment of genetically inherited diseases. Through its innovative approach, ImmuMetrix aims to enhance patient outcomes by leveraging advanced diagnostic tools in the field of immunology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.